Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
Healthcare
$17.03 -0.42%
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
52W Low $10.44High $21.03
Volume 10.02M
Average 0.43M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$238.54M
FY 2025 · Annual
Investing Cash Flow
-$105.28M
FY 2025 · Annual
Financing Cash Flow
-$3.25M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (265.07M) | (92.82M) | (55.19M) | (56.42M) | 105.9M |
| Depreciation & Amortization | 8.6M | 7.02M | 4.26M | 3.62M | 5.64M |
| Deferred Income Tax | 0 | 0 | 3.21M | (7.57M) | (11.52M) |
| Stock-Based Compensation | 62.06M | 39.73M | 25.37M | 21.39M | 18.48M |
| Change in Working Capital | (39.55M) | 42.35M | (8.34M) | 20.36M | 120.47M |
| Accounts Receivables | 1.8M | (2.72M) | (689K) | (966K) | (27.1M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (3.53M) | (1.61M) | 6K | 750K | 326K |
| Other Working Capital | (37.82M) | 46.68M | (7.66M) | 20.57M | 147.24M |
| Other Non-Cash Items | 26.1M | (183.28M) | 3.7M | 7.09M | (423K) |
| Operating Cash Flow | (207.86M) | (186.99M) | (27M) | (11.54M) | 238.54M |
| Capital Expenditures | (3.41M) | (572K) | (2.49M) | (332K) | (42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (158.31M) | (103.15M) | (134.53M) | (143.04M) | (248.22M) |
| Sales of Investments | 286.2M | 158.02M | 102.81M | 155.65M | 142.98M |
| Other Investing Activities | 6K | 1.1B | 1.51M | 0 | 0 |
| Investing Cash Flow | 124.49M | 1.15B | (32.7M) | 12.28M | (105.28M) |
| Debt Repayment | (10.73M) | (631.6M) | 0 | 0 | 0 |
| Common Stock Issued | 108.18M | 0 | 0 | 99K | 786K |
| Common Stock Repurchased | (9.06M) | (132.28M) | (199.55M) | (3.1M) | (4.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 5.08M | 618K | 508K | 0 |
| Financing Cash Flow | 91.86M | (758.81M) | (198.93M) | (2.5M) | (3.25M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.5M | 208.21M | (258.63M) | (1.75M) | 130.01M |
| Free Cash Flow | (211.26M) | (187.56M) | (29.49M) | (11.87M) | 238.5M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$105.9M
+ D&A$5.6M
+ Stock-Based Comp$18.5M
- Deferred Tax-$11.5M
+ Working Capital$120.5M
- Other Non-Cash-$423.0K
= Operating Cash Flow$238.5M
- Capex-$42.0K
= Free Cash Flow$238.5M
Analysis
FY2025 free cash flow is $238.5M. FCF conversion is 225.2% of net income. Operating cash flow was $238.5M, with capex of -$42.0K. The largest bridge item is Working Capital at $120.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Sep 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| S-8 POS | S-8 POS filing | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 |
Does TBPH generate free cash flow?
Theravance Biopharma, Inc. (TBPH) generated $238.50M of free cash flow in fiscal 2025.
How much operating cash flow does TBPH produce?
Operating cash flow was $238.54M, before capital expenditures of $42,000.00.
Continue the stock analysis
Jump to another research area for this company.